

To: Christian Holmes[cholmes@theranos.com]; Daniel Edlin[dedlin@theranos.com]; Elizabeth Holmes[eholmes@theranos.com]; Sunny Balwani[sbalwani@theranos.com]; Jeffrey Blickman[jblickman@theranos.com]

From: Daniel Young

Sent: Wed 8/14/2013 2:01:27 AM

Importance: Normal

Subject: demo results 8_13_2013

Received: Wed 8/14/2013 2:01:30 AM

[Lab Report Template 8 13 2013 v2.xlsx](#)

[Lab Report 8 13 2013 BW.pdf](#)

[Lab Report 8 13 2013 BF.pdf](#)

[Lab Report 8 13 2013 NJ.pdf](#)

[Lab Report 8 13 2013 RH.pdf](#)

[Lab Report 8 13 2013 SH.pdf](#)

[Lab Report 8 13 2013 ML.pdf](#)

Please see attached demo results for the 6 subjects. The excel file contains each report, and I also attached each report as a PDF with the subject initials.

I "corrected" assay results that I attributed to BCD collection problems. The GC results look good after such cleanup. As you will see, we did complete one full Chem14/Lipid panel on one subject, while the other subjects had lipids and a collection of other metabolic markers performed.

Each subject at a complete CBC with diff. The CBC data is very nice.

Each subject had the Thyroid panel performed. I removed the Thyroid results that I felt were questionable. There are a few out of range results left in the report, but they are very close to the reference range. (Note that I think there is something wrong with the TT3 assay/reagents, and am following up with Sharada. I removed all TT3 results.)

Please let me know if you have any questions.

Thanks,

Daniel Young, PhD

Vice President, Theranos Systems

Theranos, Inc

1601 S. California Ave

Palo Alto, CA 94304

650-470-6119 (office)

mobile)

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT – This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which it is addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 3200 Hillview Avenue, Palo Alto, CA, 94304

650-838-9292 www.theranos.com

File Produced in Native Format



Theranos Test Report Technology Demonstration

Theranos, Inc.
1601 S. California Ave, Palo Alto CA 94304

8/13/2013

PATIENT INFORMATION

PATIENT NO.	987654321
D.O.B.	Unknown
AGE / GENDER	N/A / M
PT MEDICATIONS	Unknown
ORDERING MD	N/A *Technology Demonstration*

TEST DETAIL

SPECIMEN (S) COLLECTED	8/13/2013
LAB ACCOUNT NO.	N/A *Technology Demonstration*
SPECIMEN (S) COLLECTED	Blood
DATE REPORTED	8/13/2013
COMMENTS	Non-fasting; *Technology Demonstration*

METABOLIC MARKERS

TEST NAME	PATIENT'S RESULTS	REF. RANGE	UNITS
Alkaline Phosphatase			U/L
Aspartate Aminotransferase			U/L
Calcium			mg/dL
Carbon Dioxide			mEq/L
Chloride			mEq/L
Glucose			mg/dL
Potassium			mEq/L
Sodium			mmol/L

Key: L = Slightly Below Reference Range, H = Slightly Above Reference Range, WNL = Within Normal Limits, * = Critical Value
**Reference range is for non-fasting; results fluctuate across the range based on fasting state

LIPID PANEL

TEST NAME	PATIENT'S RESULTS	REF. RANGE	UNITS
Triglycerides			mg/dL
HDL Cholesterol			mg/dL
LDL Cholesterol (calc)			mg/dL
Total Cholesterol			mg/dL
VLDL Cholesterol			mg/dL

Key: L = Slightly Below Reference Range, H = Slightly Above Reference Range, WNL = Within Normal Limits, * = Critical Value